Literature DB >> 8594075

Cyclin D and retinoblastoma gene product expression in actinic keratosis and cutaneous squamous cell carcinoma in relation to p53 expression.

T Bito1, M Ueda, N U Ahmed, T Nagano, M Ichihashi.   

Abstract

Abnormality of the molecules regulating the cell cycle has been shown to lead cells to transformation. Recently, overexpression of cyclin D protein, one of the G1 cyclins, and the abnormality of the retinoblastoma gene have been found in various human cancers. We analyzed the expression of cyclin D, retinoblastoma gene product (pRB) and p53 in actinic keratoses (AKs) and cutaneous squamous cell carcinomas (SCCs) by immunohistochemistry to elucidate the role of these molecules in keratinocyte carcinogenesis. In the normal epidermis, a few cyclin D positive cells were seen mainly at the basal layer. In 11 seborrheic keratoses, no overexpression of cyclin D was observed. Twelve of 26 AKs (46%) and 27 of 45 SCCs (60%) showed cyclin D overexpression. A few pRB positive cells were seen in the basal layer and in the suprabasal spinous layer of the normal epidermis. An abnormality of pRB, loss of expression, was seen in 2 of 26 AKs (8%) and 7 of 45 SCCs (16%). p53 protein was positive in 12 of 26 AKs (46%) and 24 of 45 SCCs (53%). Forty-five SCCs examined were divided into 22 ultraviolet (UV)-related SCCs and 23 UV-unrelated SCCs. Though UV-related SCCs showed a significantly higher incidence of p53 positivity, as previously reported by us, no significant difference in cyclin D overexpression and loss of the pRB expression was observed between UV-related and UV-unrelated SCCs. These results suggest that cyclin D overexpression is frequently involved in keratinocyte carcinogenesis and that this is an early event, as well as p53 abnormality. In addition, abnormality of the retinoblastoma gene is also related to epidermal cell carcinogenesis, though the frequency is relatively low.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8594075     DOI: 10.1111/j.1600-0560.1995.tb00758.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  12 in total

1.  Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.

Authors:  Wusheng Yan; Ignacio I Wistuba; Michael R Emmert-Buck; Heidi S Erickson
Journal:  Am J Cancer Res       Date:  2011-01-01       Impact factor: 6.166

2.  The vitamin D receptor: a tumor suppressor in skin.

Authors:  Daniel David Bikle
Journal:  Discov Med       Date:  2011-01       Impact factor: 2.970

Review 3.  Protective role of vitamin D signaling in skin cancer formation.

Authors:  Daniel D Bikle; Hashem Elalieh; Joellen Welsh; Dennis Oh; James Cleaver; Arnaud Teichert
Journal:  J Steroid Biochem Mol Biol       Date:  2012-10-08       Impact factor: 4.292

Review 4.  Protective actions of vitamin D in UVB induced skin cancer.

Authors:  Daniel D Bikle
Journal:  Photochem Photobiol Sci       Date:  2012-12       Impact factor: 3.982

Review 5.  Vitamin D and the skin: Physiology and pathophysiology.

Authors:  Daniel D Bikle
Journal:  Rev Endocr Metab Disord       Date:  2012-03       Impact factor: 6.514

6.  In Silico Analysis Validates Proteomic Findings of Formalin-fixed Paraffin Embedded Cutaneous Squamous Cell Carcinoma Tissue.

Authors:  Ali Azimi; Kimberley L Kaufman; Marina Ali; Steven Kossard; Pablo Fernandez-Penas
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

Review 7.  Vitamin D and the skin.

Authors:  Daniel D Bikle
Journal:  J Bone Miner Metab       Date:  2010-01-27       Impact factor: 2.626

Review 8.  Vitamin D receptor, a tumor suppressor in skin.

Authors:  Daniel D Bikle
Journal:  Can J Physiol Pharmacol       Date:  2014-12-08       Impact factor: 2.273

9.  The protective role of vitamin d signaling in non-melanoma skin cancer.

Authors:  Daniel D Bikle; Yan Jiang
Journal:  Cancers (Basel)       Date:  2013-11-05       Impact factor: 6.639

10.  Vitamin D receptor, UVR, and skin cancer: a potential protective mechanism.

Authors:  Daniel D Bikle
Journal:  J Invest Dermatol       Date:  2008-10       Impact factor: 7.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.